San Antonio, Texas, 78209, United States
NCT Number: NCT01188304
A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers
This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with aspirin on renal function, renin-angiotensin system and platelet aggregation in healthy volunteers. Volunteers will be randomized to receive daily doses of aleglitazar or placebo in combination with aspirin. The anticipated time on study drug is 5 weeks.
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy volunteers, aged 40 to 65 years inclusive
- Body Mass Index (BMI) between 18 and 35 kg/m2 inclusive
- Females of child-bearing potential must be willing to use two acceptable methods of contraception during the study and at least 3 months before start of the study
- Non-smoker or currently smoking less than 5 cigarettes (or equivalent amount of other tobacco products) per day and is willing and able to stop smoking during the period in study center
- Volunteer drinks no more than 3 cups of coffee, tea or soft drinks per day and is willing and able to stop drinking coffee, tea and soft drinks during the period in study center
Exclusion criteria
- Any clinically relevant abnormal laboratory test results at screening
- Volunteer has taken any prescribed, herbal or over-the-counter medication within 2 weeks prior to first dosing
- A history of any clinical significant gastro-intestinal, cardiovascular, musculoskeletal, endocrine, hematological, psychiatric, renal, hepatic, bronchopulmonary or neurological conditions or lipid disorders
- A positive test for human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B or hepatitis C
- History of intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin, history of gastric or duodenal ulceration, personal or family history of abnormal clotting or bleeding
Treatment and study plan
aleglitazar
Drugrepeated daily doses
Aspirin
Drugrepeated daily doses
Placebo
Drugrepeated daily doses
Primary outcomes
-
To investigate the effect of aleglitazar in combination with aspirin on measured glomerular filtration rate
Time frame: 13 weeks
Secondary outcomes
-
To investigate the effect of aleglitazar in combination with aspirin on renal plasma flow, filtration fraction and estimated glomerular filtration rate
Time frame: 13 weeks
-
To investigate the effect of aleglitazar in combination with aspirin on renin-angiotensin system and on anti-diuretic hormone
Time frame: 13 weeks
-
To investigate the effect of aspirin in combination with aleglitazar on platelet function and serum thromboxane B2
Time frame: 13 weeks
-
To investigate the pharmacokinetics of aleglitazar when co-administered with aspirin
Time frame: 13 weeks
-
To investigate safety and tolerability of aleglitazar
Time frame: 13 weeks
-
To investigate the effect of aleglitazar in combination with aspirin on electrolytes and osmolality clearances
Time frame: 13 weeks
Sponsors and collaborators
Lead sponsor
Hoffmann-La Roche
Industry
Registry information
Official study title
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of 150 µg Aleglitazar Once Daily in Healthy Subjects Treated With 325 mg Aspirin Once Daily on Renal Function, Renin-angiotensin System and Platelet Aggregation
Important dates
- Study start
- 2010
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- Aug 25, 2010
- Registry last updated
- Nov 2, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
NCT07502417
Healthy Volunteer
Grayslake, Illinois, United States
View Trial DetailsLinks Between Inflammation and Cardiometabolic Diseases
NCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsA Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
NCT06717269
Healthy Volunteer
Lincoln, Nebraska, United States
View Trial DetailsDiagnosis and History Study of Patients With Different Neurological Conditions
NCT00001367
Healthy Volunteer, Nervous System Disease
Bethesda, Maryland, United States
View Trial Details